OCGN – Ocugen, Inc.
Ocugen, Inc.OCGN
$1.24Name : Ocugen, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $419,767,104.00
EPSttm : -0.24
Ocugen, Inc.
$1.24
1.59%$0.02
OCGN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
24.35
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
0.01
EPS Last/This Y
0.01
EPS This/Next Y
-0.01
Price
1.23
Target Price
11.43
Analyst Recom
1
Performance Q
-29.94
Upside
-749.2%
Beta
2.21
Ticker: OCGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | OCGN | 1.48 | 0.23 | 0.44 | 82138 |
| 2026-05-12 | OCGN | 1.48 | 0.23 | 0.83 | 82730 |
| 2026-05-13 | OCGN | 1.46 | 0.24 | 0.67 | 85163 |
| 2026-05-14 | OCGN | 1.455 | 0.23 | 0.82 | 83726 |
| 2026-05-15 | OCGN | 1.395 | 0.23 | 0.64 | 84285 |
| 2026-05-18 | OCGN | 1.345 | 0.19 | 0.07 | 71630 |
| 2026-05-19 | OCGN | 1.31 | 0.18 | 0.02 | 74998 |
| 2026-05-20 | OCGN | 1.365 | 0.18 | 0.08 | 75658 |
| 2026-05-21 | OCGN | 1.34 | 0.18 | 0.03 | 75998 |
| 2026-05-22 | OCGN | 1.335 | 0.18 | 0.03 | 76168 |
| 2026-05-26 | OCGN | 1.345 | 0.17 | 0.10 | 76560 |
| 2026-05-27 | OCGN | 1.385 | 0.18 | 0.27 | 77140 |
| 2026-05-28 | OCGN | 1.405 | 0.18 | 0.02 | 79115 |
| 2026-05-29 | OCGN | 1.4 | 0.18 | 0.01 | 79446 |
| 2026-06-02 | OCGN | 1.34 | 0.18 | 0.03 | 80076 |
| 2026-06-03 | OCGN | 1.3 | 0.18 | 0.36 | 80244 |
| 2026-06-04 | OCGN | 1.375 | 0.18 | 0.10 | 80563 |
| 2026-06-05 | OCGN | 1.285 | 0.18 | 0.29 | 80835 |
| 2026-06-08 | OCGN | 1.255 | 0.18 | 0.01 | 80875 |
| 2026-06-09 | OCGN | 1.225 | 0.18 | 0.36 | 80823 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | OCGN | 1.48 | -3.3 | - | -0.22 |
| 2026-05-12 | OCGN | 1.48 | -3.3 | - | -0.22 |
| 2026-05-13 | OCGN | 1.46 | -3.3 | - | -0.22 |
| 2026-05-14 | OCGN | 1.46 | -3.3 | - | -0.22 |
| 2026-05-15 | OCGN | 1.39 | -3.3 | - | -0.22 |
| 2026-05-18 | OCGN | 1.35 | -3.3 | - | -0.22 |
| 2026-05-19 | OCGN | 1.31 | -3.3 | - | -0.22 |
| 2026-05-20 | OCGN | 1.37 | -3.3 | - | -0.22 |
| 2026-05-21 | OCGN | 1.34 | -3.3 | - | -0.22 |
| 2026-05-22 | OCGN | 1.34 | -3.3 | - | -0.22 |
| 2026-05-26 | OCGN | 1.35 | -3.3 | - | -0.22 |
| 2026-05-27 | OCGN | 1.39 | -3.3 | - | -0.22 |
| 2026-05-28 | OCGN | 1.40 | -3.3 | - | -0.22 |
| 2026-05-29 | OCGN | 1.38 | -3.3 | - | -0.22 |
| 2026-06-01 | OCGN | 1.36 | -6.7 | - | -0.22 |
| 2026-06-02 | OCGN | 1.35 | -6.7 | - | -0.22 |
| 2026-06-03 | OCGN | 1.30 | -6.7 | - | -0.22 |
| 2026-06-04 | OCGN | 1.38 | -6.7 | - | -0.22 |
| 2026-06-05 | OCGN | 1.29 | -6.7 | - | -0.22 |
| 2026-06-08 | OCGN | 1.25 | -6.7 | - | -0.22 |
| 2026-06-09 | OCGN | 1.23 | -6.7 | - | -0.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | OCGN | 0.00 | 11.16 | 20.63 |
| 2026-05-12 | OCGN | 0.00 | 11.16 | 21.17 |
| 2026-05-13 | OCGN | 0.00 | 11.16 | 21.17 |
| 2026-05-14 | OCGN | 0.00 | 11.16 | 21.17 |
| 2026-05-15 | OCGN | 0.00 | 11.16 | 21.17 |
| 2026-05-18 | OCGN | 0.00 | 11.02 | 21.16 |
| 2026-05-19 | OCGN | 0.00 | 11.02 | 21.16 |
| 2026-05-20 | OCGN | 0.00 | 11.02 | 21.16 |
| 2026-05-21 | OCGN | 0.00 | 11.02 | 21.16 |
| 2026-05-22 | OCGN | 0.00 | 11.02 | 21.16 |
| 2026-05-26 | OCGN | 0.00 | 23.25 | 21.16 |
| 2026-05-27 | OCGN | 0.00 | 23.25 | 21.16 |
| 2026-05-28 | OCGN | 0.00 | 23.25 | 24.61 |
| 2026-05-29 | OCGN | 0.00 | 23.25 | 24.61 |
| 2026-06-02 | OCGN | 0.00 | 22.34 | 24.35 |
| 2026-06-03 | OCGN | 0.00 | 22.34 | 24.35 |
| 2026-06-04 | OCGN | 0.00 | 22.34 | 24.35 |
| 2026-06-05 | OCGN | 0.00 | 22.34 | 24.35 |
| 2026-06-08 | OCGN | 0.00 | 22.36 | 24.35 |
| 2026-06-09 | OCGN | 0.00 | 22.36 | 24.35 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
22.36
Beta
2.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
11
Growth Score
32
Sentiment Score
37
Actual DrawDown %
93.1
Max Drawdown 5-Year %
-97.7
Target Price
11.43
P/E
Forward P/E
372.37
PEG
P/S
94.12
P/B
72.26
P/Free Cash Flow
EPS
-0.23
Average EPS Est. Cur. Y
-0.22
EPS Next Y. (Est.)
-0.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1605.22
Relative Volume
0.54
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
OCGN
Healthcare
$1.24
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
33.7
Range 1M
4%
Sup Dist
0.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
1.9%
EPS NY
101.5%
52W%
18.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+821.8% upside
Upside
+821.8%
Quality
11
Ocugen, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 116
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
OCGN
Latest News
—
Caricamento notizie per OCGN…
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading